AZI2

Across TCGA pan-cancer cohorts, AZI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AZI2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AZI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AZI2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

LSCC, CCRCC, and GBM are the cancer types where AZI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.865	1.000	.008	18	view →
CCRCC	OS	Tertile	All	0.983	0.525	.012	16	view →
GBM	OS	Tertile	All	0.656	0.893	.008	11	view →
UCEC	OS	Tertile	All	1.000	0.908	.036	4	view →
HNSC	OS	Quartile	II,III,IV	0.682	0.887	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AZI2–LSCC (DFS)

Open the LSCC breakdown →